Oxford BioDynamics Plc (OXBOF)
USD 0.02
(-86.0%)
USD 0.02
(-86.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.82 Million GBP | -61.34% |
| 2022 | -6.71 Million GBP | -0.42% |
| 2021 | -6.68 Million GBP | -54.93% |
| 2020 | -4.31 Million GBP | -54.04% |
| 2019 | -2.8 Million GBP | -43.37% |
| 2018 | -1.95 Million GBP | 48.66% |
| 2017 | -3.8 Million GBP | -119.88% |
| 2016 | -1.73 Million GBP | -72.14% |
| 2015 | -1 Million GBP | -36.55% |
| 2014 | -736 Thousand GBP | 30.24% |
| 2013 | -1.05 Million GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.36 Million GBP | 0.0% |
| 2024 Q1 | -2.36 Million GBP | 62.99% |
| 2023 Q2 | -4.44 Million GBP | -100.0% |
| 2023 Q1 | -2.22 Million GBP | 39.65% |
| 2023 Q4 | -6.38 Million GBP | -100.0% |
| 2023 Q3 | -3.19 Million GBP | 28.17% |
| 2023 FY | -10.82 Million GBP | -61.34% |
| 2022 Q3 | -1.91 Million GBP | 36.91% |
| 2022 FY | -6.71 Million GBP | -0.42% |
| 2022 Q1 | -1.44 Million GBP | 59.92% |
| 2022 Q2 | -3.02 Million GBP | -109.76% |
| 2022 Q4 | -3.68 Million GBP | -92.62% |
| 2021 Q4 | -3.6 Million GBP | -100.0% |
| 2021 Q2 | -3.07 Million GBP | -100.0% |
| 2021 Q1 | -1.53 Million GBP | 32.68% |
| 2021 FY | -6.68 Million GBP | -54.93% |
| 2021 Q3 | -1.8 Million GBP | 41.49% |
| 2020 FY | -4.31 Million GBP | -54.04% |
| 2020 Q2 | -2.02 Million GBP | -100.0% |
| 2020 Q3 | -1.16 Million GBP | 42.67% |
| 2020 Q1 | -1.01 Million GBP | 33.36% |
| 2020 Q4 | -2.28 Million GBP | -96.9% |
| 2019 FY | -2.8 Million GBP | -43.37% |
| 2019 Q1 | -640 Thousand GBP | -55.91% |
| 2019 Q4 | -1.52 Million GBP | -100.0% |
| 2019 Q2 | -640 Thousand GBP | 0.0% |
| 2019 Q3 | -760 Thousand GBP | -18.75% |
| 2018 FY | -1.95 Million GBP | 48.66% |
| 2018 Q1 | -566 Thousand GBP | 2.67% |
| 2018 Q2 | -566 Thousand GBP | 0.0% |
| 2018 Q3 | -410.5 Thousand GBP | 27.47% |
| 2018 Q4 | -410.5 Thousand GBP | 0.0% |
| 2017 Q3 | -581.5 Thousand GBP | 55.96% |
| 2017 FY | -3.8 Million GBP | -119.88% |
| 2017 Q4 | -581.5 Thousand GBP | 0.0% |
| 2017 Q2 | -1.32 Million GBP | 0.0% |
| 2017 Q1 | -1.32 Million GBP | -179.77% |
| 2016 Q1 | -393 Thousand GBP | -17.66% |
| 2016 Q2 | -393 Thousand GBP | 0.0% |
| 2016 Q4 | -472 Thousand GBP | 0.0% |
| 2016 FY | -1.73 Million GBP | -72.14% |
| 2016 Q3 | -472 Thousand GBP | -20.1% |
| 2015 Q4 | -334 Thousand GBP | 0.0% |
| 2015 Q3 | -334 Thousand GBP | -98.22% |
| 2015 FY | -1 Million GBP | -36.55% |
| 2015 Q1 | -168.5 Thousand GBP | 0.0% |
| 2015 Q2 | -168.5 Thousand GBP | 0.0% |
| 2014 FY | -736 Thousand GBP | 30.24% |
| 2013 FY | -1.05 Million GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | -152.944% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 85.558% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -3859.737% |
| SQZ Biotechnologies Company | -79.46 Million USD | 86.376% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -274.292% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 120.435% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 116.621% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -494.663% |
| Marizyme, Inc. | -65.34 Million USD | 83.433% |
| Genus plc | 7.9 Million USD | 237.038% |
| Pharming Group N.V. | -10.54 Million USD | -2.636% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -398.937% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -191.788% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -22.411% |
| ContraFect Corporation | -65.15 Million USD | 83.384% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -526.702% |
| IMV Inc. | -36.48 Million USD | 70.328% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -34.323% |
| ONE Bio Corp. | 8.67 Million USD | 224.772% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 79.057% |
| Mesoblast Limited | -87.95 Million USD | 87.692% |
| MultiCell Technologies, Inc. | -380.07 USD | -2848322.659% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -190.008% |
| Genscript Biotech Corporation | -95.47 Million USD | 88.661% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1611.872% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -354.708% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -64.626% |
| Biomind Labs Inc. | -1.21 Million USD | -791.529% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -249.027% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -36.984% |
| Skye Bioscience, Inc. | -37.64 Million USD | 71.242% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -455.393% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 0.604% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -72188.996% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -121.569% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -55.037% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 31.789% |
| Accustem Sciences Inc. | -3.74 Million USD | -188.969% |
| EV Biologics, Inc. | -1.26 Million USD | -754.369% |
| Q BioMed Inc. | -2.05 Million USD | -427.559% |
| GB Sciences, Inc. | -1.36 Million USD | -695.049% |
| Alpha Cognition Inc. | -13.77 Million USD | 21.394% |
| CSL Limited | 2.64 Billion USD | 100.41% |
| Agentix Corp. | -1.37 Million USD | -687.798% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 81.874% |
| Enzolytics Inc. | -2.17 Million USD | -397.328% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | -199.889% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -241.36% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -86.102% |
| argenx SE | -295.05 Million USD | 96.331% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 82.706% |
| HST Global, Inc. | -146.21 Thousand USD | -7304.418% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 11146.939% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -516.947% |
| Halberd Corporation | -79.67 Thousand USD | -13487.529% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 256.341% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -257.75% |
| Zenith Capital Corp. | -10.59 Million USD | -2.171% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -172.49% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -161.123% |
| AVAX Technologies, Inc. | -6.41 Million USD | -68.796% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -17811.798% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -439.919% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -46479.468% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -126.999% |
| Helix BioMedix, Inc. | -1.05 Million USD | -925.134% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -183.477% |
| Kadimastem Ltd | -3.3 Million USD | -227.327% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | -27.62% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -2352.823% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -710.675% |
| LadRx Corporation | 400.44 Thousand USD | 2803.506% |
| Cell Source, Inc. | -5.32 Million USD | -103.45% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2505.667% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1157.735% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1157.735% |
| Affymax, Inc. | -14.42 Million USD | 24.945% |
| Mobile Lads Corp. | -2.26 Million USD | -378.33% |
| Itoco Inc. | -1.86 Million USD | -479.242% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -143.69% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -548.652% |
| International Stem Cell Corporation | -131 Thousand USD | -8164.122% |
| CytoDyn Inc. | -49.84 Million USD | 78.279% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -13598.075% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -4645.602% |
| Qrons Inc. | -789.34 Thousand USD | -1271.513% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1049.832% |
| SYBLEU INC | -180.3 Thousand USD | -5904.304% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -418.566% |
| Rebus Holdings, Inc. | -1.02 Million USD | -961.373% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -571.281% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -19847.671% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -327.863% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 77.48% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -412.11% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1286.372% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -241.73% |
| Neutra Corp. | -233.46 Thousand USD | -4537.098% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 46.646% |
| PureTech Health plc | -65.69 Million USD | 83.521% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 49.094% |
| IXICO plc | -1.17 Million USD | -819.015% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -9.056% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 81.05% |
| CSL Limited | 2.64 Billion USD | 100.41% |
| Cellectis S.A. | -103.17 Million USD | 89.507% |